Tion of X-linked severe GW9662 msds combined immunodeficiency by ex vivo gene therapy.
Tion of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002, 346(16):1185?193. 12. Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288(5466):669?72. 13. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder D, Gilmour KC, Adams S, Thornhill SI, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, Kinnon C, Ancliff P, Webb DK, Schmidt M, von Kalle C, Gaspar HB, Thrasher AJ: Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008, 118(9):3143?150. 14. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Kramer A, Schwable J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Gohring G, Schwarzwaelder K, Hofmann WK, Karakaya K, Tchatchou S, Yang R, Reinecke P, Kuhlcke K, Schlegelberger B, Thrasher AJ, Hoelzer D, Seger R, von Kalle C, Grez M: Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature medicine 2010, 16(2):198?04. 15. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kuhlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Luthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M: Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28993237 PRDM16 or SETBP1. Nature medicine 2006, 12(4):401?09. 16. Vijaya S, Steffen DL, Robinson HL: Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J Virol 1986, 60(2):683?92. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27486068 17. Wu X, Li Y, Crise B, Burgess SM: Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300(5626):1749?751. 18. Cattoglio C, Pellin D, Rizzi E, Maruggi G, Corti G, Miselli F, Sartori D, Guffanti A, Di Serio C, Ambrosi A, De Bellis G, Mavilio F: High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood 2010, 116(25):5507?517. 19. Roth SL, Malani N, Bushman FD: Gammaretroviral Integration into Nucleosomal Target DNA In Vivo. J Virol 2011, 85(14):7393?401.20. Biasco L, Ambrosi A, Pellin D, Bartholomae C, Brigida I, Roncarolo MG, Di Serio C, Von Kalle C, Schmidt M, Aiuti A: Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol Med 2011, 3(2):89?01. 21. Moiani A, Miccio A, Rizzi E, Severgnini M, Pellin D, Suerth JD, Baum C, De Bellis G, Mavilio F: Deletion of the LTR enhancer/promoter has no impact on the integration profile of MLV vectors in human hematopoietic progenitors. PLoS One 2013, 8(1):e55721. 22. Lafave MC, Varshney GK, Gildea DE, Wolfsberg TG, Baxevanis AD, Burgess SM: MLV integration site selection is driven by strong enhancers and active promoters. Nucleic Acids Res 2014, 42(7):4257?269. 23. Santoni FA, Hartley O, Luban J: Deciphering the code for retroviral integration target site selection. PLoS Comput Biol 2010, 6(11):e1001008. 24. De Ravi.